IDXG insider transaction filings
INTERPACE BIOSCIENCES, INC. — 12 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-20. Screen IDXG transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 6 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 13.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Burnell Thomas W. — CEO, President & Chairman, Director | 1 | — | — | 5 |
| McCarthy Christopher — CFO & COO | 1 | — | — | 4 |
| AGGARWAL VIJAY — Director | 1 | — | — | 1 |
| KEEGAN JOSEPH D — Director | 1 | — | — | 1 |
| Rocca Fortunato R. — Director | 1 | — | — | 1 |
| SULLIVAN STEPHEN J — Director | 1 | — | — | 1 |
Recent Form 4 filings — INTERPACE BIOSCIENCES, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-20 | 4 | Burnell Thomas W. — CEO, President & Chairman, Director | Option exercise (M): 1,966,763 @ $0 · Tax withholding (F): 581,718 @ $1.61 · Grant/award (A): 1,966,763 (derivative) @ $0 · Option exercise (M): 1,966,763 (derivative) @ $0 · Grant/award (A): 554,018 (derivative) @ $0 | EDGAR |
| 2026-08-20 | 4 | AGGARWAL VIJAY — Director | Grant/award (A): 69,252 (derivative) @ $0 | EDGAR |
| 2026-08-20 | 4 | KEEGAN JOSEPH D — Director | Grant/award (A): 69,252 (derivative) @ $0 | EDGAR |
| 2026-08-20 | 4 | Rocca Fortunato R. — Director | Grant/award (A): 69,252 (derivative) @ $0 | EDGAR |
| 2026-08-20 | 4 | McCarthy Christopher — CFO & COO | Option exercise (M): 277,009 @ $0 · Grant/award (A): 554,018 (derivative) @ $0 · Option exercise (M): 277,009 (derivative) @ $0 · Grant/award (A): 277,009 (derivative) @ $0 | EDGAR |
| 2026-08-20 | 4 | SULLIVAN STEPHEN J — Director | Grant/award (A): 69,252 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | 1315 Capital II, L.P. — 10% owner | Conversion (C): 9,405,941 @ $2.02 · Conversion (C): 19,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Ampersand 2018 Limited Partnership — 10% owner | Conversion (C): 13,861,386 @ $2.02 · Conversion (C): 28,000 (derivative) @ $0 | EDGAR |
| 2025-04-25 | 4 | McCarthy Christopher — Chief Financial Officer | Option exercise (M): 7,556 @ $0 · Option exercise (M): 1,095 @ $0 · Option exercise (M): 7,556 @ $0 · Option exercise (M): 6,045 @ $0 · Option exercise (M): 15,112 @ $0 · Option exercise (M): 1,111 @ $0 | EDGAR |
| 2024-10-15 | 4 | 1315 Capital II, L.P. — 10% owner | Disposition to issuer (D): 19,000 (derivative) · Grant/award (A): 19,000 (derivative) | EDGAR |
| 2024-10-15 | 4 | Ampersand 2018 Limited Partnership — 10% owner | Disposition to issuer (D): 28,000 (derivative) · Grant/award (A): 28,000 (derivative) | EDGAR |
| 2024-02-06 | 4 | McCarthy Christopher — Chief Financial Officer | Grant/award (A): 10,000 @ $0 | EDGAR |
Recent 8-K events — INTERPACE BIOSCIENCES, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-27 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-26 | 8-K/A | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-21 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-01 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-20 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-03 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-08 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=IDXG returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →